B+
Bull case
25%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
AMRN
AmarinCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$14.50
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-05
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+62.3
Score
AI commentary
Primary-company commentary is constructive on international demand, the Recordati partnership, cost reduction and cash flow, but coverage is sparse and the packet provides no usable analyst revisions, options, insider or social data. Revenue contraction, early commercialization and weak peer evidence keep conviction tentative.
RankAlpha Sentiment Codex - 2026-09-05
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-12-04eventRecordati-led international commercialization milestonesHigh impact
Recordati’s rollout remains early, but Amarin reported improving pricing, reimbursement, market access and adoption, with Singapore and South Korea progressing toward anticipated near-term commercialization [#SEC-8K-2026-07-29].
2026-12-31catalystRecordati partnership monetization across licensed marketsHigh impact
Amarin’s exclusive long-term license and supply agreement with Recordati covers 59 countries focused in Europe. Early progress in pricing, reimbursement, market access and adoption creates a multi-quarter monetization path, but execution remains unproven [#SEC-8K-2026-07-29].
2026-12-31catalystLower cost base and cash-flow validationHigh impact
Amarin completed its $70 million annual cost-savings initiative, generated positive cash flow for a third consecutive quarter, remained debt-free, and expects positive cash-flow generation with approximately 10% year-end cash growth [#SEC-8K-2026-07-29].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-05 • Updated nightlySource: Internal modelMethodology